Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Santana Gomes, A., Contreras Mejía, F., Reiss, A., Ayhan, A., Lee, J., Saevets, V., Zagouri, F., Gilbert, L., Sehouli, J., Tharavichitkul, E., Lindemann, K., Lazzari, R., Chang, C.,
Lampé, R., Zhu, H., Oaknin, A., Christiaens, M., Polterauer, S., Usami, T., Li, K., Yamada, K., Toker, S., Keefe, S., Pignata, S., Duska, L., ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators:
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet. 403 (10434), 1341-1350, 2024.
Folyóirat-mutatók:
D1 Medicine (miscellaneous) (2023)